(Reuters) – U.S. genetic testing Illumina on Thursday trimmed its annual profit forecast for the second straight quarter, hurt by weakness in demand for its sequencing instruments, consumables and services. …
illumina
-
-
By Mike Scarcella (Reuters) – A U.S. appeals court on Tuesday said it will accelerate reviewing Illumina Inc’s challenge to a federal agency order requiring the biotechnology company to divest …
-
By Blake Brittain (Reuters) – Gene-sequencing giant Illumina Inc has settled a patent lawsuit brought by Maryland biotech company Ravgen Inc, which accused Illumina’s genetic tests of infringing its patents. …
-
(Reuters) – Activist investor Carl Icahn is preparing a proxy fight at Illumina Inc, arguing that the life science maker’s acquisition of Grail Inc cost its shareholders roughly $50 billion, …
-
(Reuters) – Illumina Inc said on Monday it was cutting 5% of its global workforce to realign its operating expenses as stubborn inflation and a strong dollar weigh on the …
-
(Reuters) – A judge has ruled in favor of Illumina Inc in its acquisition of Grail Inc dealing a blow to the U.S. Federal Trade Commission’s efforts to unwind the …
-
BRUSSELS – EU antitrust regulators are expected to veto U.S. life sciences firm Illumina’s acquisition of biotechnology company Grail, people familiar with the matter said on Wednesday. There are doubts …
-
By Foo Yun Chee LUXEMBOURG -U.S. life sciences company Illumina on Wednesday lost its challenge against European Union scrutiny of its $8 billion cash-and-stock takeover of Grail, as a top …
-
By Foo Yun Chee BRUSSELS – A European court will decide on July 13 whether U.S. life sciences company Illumina’s $8 billion cash-and-stock takeover of Grail should be scrutinised by …
-
By Foo Yun Chee LUXEMBOURG – U.S. life sciences company Illumina on Thursday criticised EU antitrust regulators for scrutinising its $8 billion cash-and-stock takeover of Grail even though the cancer detection test maker …